Tango Therapeutics, Inc.
NASDAQ:TNGX
2.83 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 11.607 | 19.875 | 6.471 | 5.431 | 10.732 | 14.598 | 5.766 | 6.411 | 6.92 | 5.771 | 5.758 | 5.716 | 6.787 | 18.153 | 6.386 | 9.142 | -11.261 | 5.064 | 4.711 |
| Cost of Revenue
| 0 | 0.632 | 0.625 | 0.617 | 0.613 | 1.508 | 1.458 | 1.452 | 1.22 | 0.686 | 0.67 | 21.634 | 21.923 | 19.079 | 15 | 15.063 | 12.977 | 11.129 | 10.822 |
| Gross Profit
| 11.607 | 19.243 | 5.846 | 4.814 | 10.119 | 13.09 | 4.308 | 4.959 | 5.7 | 5.085 | 5.088 | -15.918 | -15.136 | -0.926 | -8.614 | -5.921 | -24.238 | -6.065 | -6.111 |
| Gross Profit Ratio
| 1 | 0.968 | 0.903 | 0.886 | 0.943 | 0.897 | 0.747 | 0.774 | 0.824 | 0.881 | 0.884 | -2.785 | -2.23 | -0.051 | -1.349 | -0.648 | 2.152 | -1.198 | -1.297 |
| Reseach & Development Expenses
| 33.263 | 38.654 | 38.065 | 31.339 | 27.149 | 28.671 | 28.039 | 29.091 | 28.744 | 23.741 | 24.33 | 21.634 | 21.923 | 19.079 | 15 | 15.063 | 12.977 | 11.129 | 10.822 |
| General & Administrative Expenses
| 11.222 | 10.773 | 10.661 | 9.105 | 9.209 | 9.174 | 8.013 | 7.887 | 8.099 | 7.232 | 6.807 | 6.066 | 4.433 | 3.63 | 3.467 | 3.016 | 2.518 | 2.378 | 1.953 |
| Selling & Marketing Expenses
| 0 | -0.632 | -0.625 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 11.222 | 10.141 | 10.036 | 9.105 | 9.209 | 9.174 | 8.013 | 7.887 | 8.099 | 7.232 | 6.807 | 6.066 | 4.433 | 3.63 | 3.467 | 3.016 | 2.518 | 2.378 | 1.953 |
| Other Expenses
| 0 | 1.995 | 2.184 | 2.061 | 1.514 | 2.601 | 2.278 | 1.558 | 0.523 | 0.05 | -0.047 | 0.115 | -0.05 | -0.062 | -0.055 | 0.002 | 0.004 | 0 | 0 |
| Operating Expenses
| 44.485 | 48.795 | 48.101 | 40.444 | 36.358 | 37.845 | 36.052 | 36.978 | 36.843 | 30.973 | 31.137 | 27.7 | 26.356 | 22.709 | 18.467 | 18.079 | 15.495 | 2.354 | 1.863 |
| Operating Income
| -32.878 | -29.552 | -42.255 | -35.013 | -25.626 | -23.247 | -30.286 | -30.567 | -29.923 | -25.202 | -24.99 | -21.984 | -19.569 | -4.556 | -12.081 | -8.937 | -26.756 | -8.443 | -8.064 |
| Operating Income Ratio
| -2.833 | -1.487 | -6.53 | -6.447 | -2.388 | -1.592 | -5.253 | -4.768 | -4.324 | -4.367 | -4.34 | -3.846 | -2.883 | -0.251 | -1.892 | -0.978 | 2.376 | -1.667 | -1.712 |
| Total Other Income Expenses Net
| 3.765 | 4.066 | 4.381 | 2.061 | 1.514 | 2.601 | 2.278 | 1.558 | 0.873 | 0.347 | -0.218 | 0.115 | -0.05 | -0.062 | -0.055 | 0.002 | 0.004 | 0.051 | 0.15 |
| Income Before Tax
| -29.113 | -25.486 | -37.874 | -30.716 | -22.24 | -20.646 | -28.008 | -29.009 | -29.05 | -24.855 | -25.208 | -21.869 | -19.528 | -4.514 | -12.032 | -8.864 | -26.802 | -8.392 | -7.914 |
| Income Before Tax Ratio
| -2.508 | -1.282 | -5.853 | -5.656 | -2.072 | -1.414 | -4.857 | -4.525 | -4.198 | -4.307 | -4.378 | -3.826 | -2.877 | -0.249 | -1.884 | -0.97 | 2.38 | -1.657 | -1.68 |
| Income Tax Expense
| -0.054 | 0.065 | 0.04 | 0.047 | 0.023 | 0.064 | -2.278 | 0.051 | -0.873 | 0.003 | -0.171 | 0.177 | 0.062 | -0.021 | 0.074 | 0 | 0.05 | 0 | 0 |
| Net Income
| -29.167 | -25.551 | -37.914 | -30.763 | -22.263 | -20.71 | -25.73 | -29.06 | -28.177 | -24.858 | -25.037 | -22.046 | -19.59 | -4.493 | -12.106 | -8.864 | -26.802 | -8.392 | -7.914 |
| Net Income Ratio
| -2.513 | -1.286 | -5.859 | -5.664 | -2.074 | -1.419 | -4.462 | -4.533 | -4.072 | -4.307 | -4.348 | -3.857 | -2.886 | -0.248 | -1.896 | -0.97 | 2.38 | -1.657 | -1.68 |
| EPS
| -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 | -0.29 | -0.33 | -0.32 | -0.28 | -0.29 | -0.25 | -0.28 | -0.051 | -0.14 | -0.53 | -0.31 | -0.75 | -0.74 |
| EPS Diluted
| -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 | -0.29 | -0.33 | -0.32 | -0.28 | -0.29 | -0.25 | -0.28 | -0.051 | -0.14 | -0.42 | -0.31 | -0.75 | -0.74 |
| EBITDA
| -32.878 | -28.92 | -41.63 | -34.396 | -25.013 | -23.247 | -30.286 | -30.567 | -29.506 | -25.202 | -25.379 | -21.984 | -19.344 | -4.556 | -11.877 | -8.746 | -26.752 | -8.266 | -7.9 |
| EBITDA Ratio
| -2.833 | -1.455 | -6.433 | -6.333 | -2.331 | -1.592 | -5.253 | -4.768 | -4.264 | -4.367 | -4.408 | -3.846 | -2.85 | -0.251 | -1.86 | -0.957 | 2.376 | -1.632 | -1.677 |